SmartPA Criteria

**Drug/Drug Class:** Selzentry® Clinical Edit

**First Implementation Date:** April 7, 2010

**Revised Date:** June 20, 2019

**Prepared for:** MO HealthNet

**Prepared by:** MO HealthNet/Conduent

**Criteria Status:** ☒ Existing Criteria
☐ Revision of Existing Criteria
☐ New Criteria

---

**Executive Summary**

**Purpose:** Ensure appropriate utilization and control of Selzentry® (maraviroc)

**Why was this Issue Selected:** Selzentry® (maraviroc) is a CCR5 (C-C chemokine receptor type 5) co-receptor antagonist indicated for the treatment of only CCR5-tropic HIV-1 infection with other antiretroviral agents. In 2016, Selzentry received FDA approval to expand its indication to include treatment of pediatric patients 2 years of age and older. Selzentry works by selectively binding to the human chemokine receptor CCR5 present on the cell membrane and preventing the interaction of HIV gp 120 and CCR5; this interaction is necessary for CCR5-tropic HIV-1 to enter cells. Selzentry is not recommended in patients with CXCR4-tropic or dual/mixed HIV-1 as it is ineffective in these cases. The Trofile™ test is used to determine if a patient's virus is suitable for a CCR5 co-receptor antagonist therapy; the results of the Trofile test will determine if Selzentry is an appropriate treatment choice for the patient. Also, as compared to treatment with Sustiva® (efavirenz), treatment-naïve adults treated with Selzentry experienced more virologic failure and lamivudine resistance; therefore Selzentry is not recommended for use in treatment-naïve patients.

**Program-Specific Information:**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Date Range FFS 1-1-2018 to 12-31-2018</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Drug</td>
</tr>
<tr>
<td>SELZENTRY 20 MG/ML SOLN</td>
<td>0</td>
</tr>
<tr>
<td>SELZENTRY 25MG TABLET</td>
<td>0</td>
</tr>
<tr>
<td>SELZENTRY 75MG TABLET</td>
<td>0</td>
</tr>
<tr>
<td>SELZENTRY 150 MG TABLET</td>
<td>33</td>
</tr>
<tr>
<td>SELZENTRY 300 MG TABLET</td>
<td>93</td>
</tr>
</tbody>
</table>

**Type of Criteria:**
- ☒ Increased risk of ADE
- ☒ Preferred Drug List
- ☑ Appropriate Indications
- ☑ Clinical Edit
- ☐ Only administrative databases
- ☑ Databases + Prescriber-supplied

---

*Note: The information is specific to MO HealthNet and may vary for other regions or organizations.*
### Setting & Population

- Drug for review: Selzentry® (maraviroc)
- Age range: All appropriate MO HealthNet participants aged 2 years and older

### Approval Criteria

- Participant has history of positive viral tropism for CCR5-tropic HIV (CPT:87999/22=Trofile test)
- Participant is HIV infected
- Participant is 2 years of age or older
- Participant is not treatment naïve (participant has been on antiretroviral medication before)
- Participant is currently on additional antiretroviral medication besides Selzentry (maraviroc)

### Denial Criteria

- Therapy will be denied if no approval criteria met

### Required Documentation

<table>
<thead>
<tr>
<th>Laboratory results:</th>
<th>X</th>
</tr>
</thead>
<tbody>
<tr>
<td>MedWatch form:</td>
<td></td>
</tr>
<tr>
<td>Progress notes:</td>
<td>X</td>
</tr>
<tr>
<td>Other:</td>
<td></td>
</tr>
</tbody>
</table>

### Disposition of Edit

Denial: Exception code “682” (Clinical Edit)

### References